The Sex Influence On Pharmacokinetic
The Sex Influence On Pharmacokinetic
The Sex Influence On Pharmacokinetic
Introduction
Inclusion of women in clinical trials and analysis of clinical trial data for
sex/gender effects have been an integral component of the US FDAs
consideration for approval of pharmaceutical products since the mid-1980s ( FDA
Guidance for Industry 1993). The study of sex differences is now a routine
component of drug development because of existing data in drug exposure and
response differences between men and women and the need to understand such
differences for proper dosing (Harris et al. 1995; Schwartz 2003; Institute of
Medicine (US) 2001; Franconi et al. 2007; Parekh et al. 2011). The resulting
expanding knowledge of sex differences in the exposure and responses to drugs
has led to a better under-standing of the mechanisms contributing to these
differences and improved pharmaco-therapy for men and women.
Sex-based differences may be due to pharmacokinetics (differences in exposure in
men and women following administration of the same dose of a drug) and/or
pharmacodynamics (differences in the bodys response to the same dose of a drug
in men and women) and can manifest as differences in safety and/or efficacy of
pharmacotherapy. For example, when compared to men, women are 1.51.7 times
more likely to develop an adverse drug reaction (Rademaker 2001), which
The views expressed are those of the authors and do not necessarily reflect official policy of the
US FDA. No official endorsement by the US FDA is intended or should be inferred.
E.O. Fadiran (*)
Office of Womens Health, Office of the Commissioner, Food and Drug Administration, Building
32, Room 2312 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA e-mail:
[email protected]
L. Zhang
Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation
and Research, Food and Drug Administration, Silver Spring, MD 20993, USA
e-mail: [email protected]
Springer International Publishing Switzerland 2015
41
M. Harrison-Woolrych (ed.), Medicines For Women,
DOI 10.1007/978-3-319-12406-3_2
42
is defined as any unintended and undesired effect of a drug used at a dose for
diagnosis, prophylaxis, or therapy (Rademaker 2001; Anderson 2005; Tran et al.
1988). This chapter will focus on sex differences in pharmacokinetics (PK) and
will discuss how these differences may affect the efficacy and safety of medicines
in women.
Date of
Date of
the cited
name)
approval
label
section
Labeling statement
ABILIFY
11/15/02
6/09/14
Use in specific
Cmax and AUC of
(Aripiprazole)
populations:
aripiprazole and its active
gender
metabolite, dehydro-
aripiprazole is lower in
explained by differences in
adjustment is recommended
based on gender.
APTIVUS
6/22/05
4/07/14
Clinical
Evaluation of steady-state
(Tipranavir)
pharmacology
plasma tipranavir trough con-
APTIVUS/ritonavir
dose adjustment.
ARZERRA
10/26/09
4/17/14
Clinical
Gender had a modest effect
(Ofatumumab)
pharmacology
on ofatumumab pharmacoki-
a cross-study population
dosage adjustment is
recommended.
(continued)
44
Date of
Date of
the cited
pharmacology
bevacizumab varied by body
females.
EMEND
3/27/03
3/27/13
Clinical
Following oral administration
(Aprepitant)
pharmacology
of a single dose of EMEND,
14 % and 22 % higher in
aprepitant is 25 % lower in
ENABLEX
12/22/04
3/15/12
Clinical
PK parameters were calcu(Darifencin
pharmacology
lated for 22 male and
Hydrobromide)
males, respectively.
FACTIVE
4/4/03
8/14/13
Clinical
There are no significant dif(Gemifloxacin
pharmacology
ferences between
Mesylate)
gemifloxacin pharmacokinet-
Population pharmacokinetic
were approximately 10 %
(continued)
Date of
Date of
the cited
name)
approval
label
section
Labeling statement
(range, 3.2142.71 gh/mL) and 8.80 gh/mL (range, 3.3347.73 gh/mL), respectively. No
gemifloxacin dosage adjustment based on gender is necessary.
FIRAZYR
8/25/11
8/30/13
Clinical
Following single-dose
(Icatibant Acetate)
pharmacology
administration of 30 mg sub-
differences (~1214 %)
Clearance of FIRAZYR is
is not warranted.
FUZEON
3/13/03
10/31/13
Clinical
Analysis of plasma concen(Enfuvirtide)
pharmacology
tration data from subjects in
46
Date of
Date of
the cited
FYCOMPA
10/22/12
2/24/14
Clinical
In a population pharmacoki(Perampanel)
pharmacology
netic analysis of patients with
on sex.
IMAGENT
5/31/02
5/31/02
Clinical
Females eliminate perflexane
(Perflexane Phos-
pharmacology
through the expired air more
pholipid
life 13 _ 4 h, N 5; male
not known.
INTERMEZZO
11/23/11
2/6/13
Use in specific
Women cleared zolpidem
(Zolpidem)
populations:
tartrate from the body after
gender
sublingual administration of a
approximately 45 % higher at
(continued)
Date of
Date of
the cited
name)
approval
label
section
Labeling statement
LIVALO
8/3/09
10/16/13
Clinical
In a pharmacokinetic study
(Pitavastatin
pharmacology
which compared healthy male
Calcium)
or safety of LIVALO in
MYCAMINE
3/16/05
6/21/13
Use in specific
No dose adjustment of
(Micafungin
populations:
Mycamine is required based
Sodium)
race and
on gender or race. After
gender
14 daily doses of 150 mg to
by approximately 23 % com-
MYRBETRIQ
6/28/12
6/28/12
Clinical pharThe Cmax and AUC of
(Mirabegron)
macology
mirabegron were approxi-
(also in race
mately 4050 % higher in
and gender
females than in males. When
section)
corrected for differences in
to males
NAMENDA
10/16/03
10/24/13
Clinical
Following multiple dose
(Memantine
pharmacology
administration of
Hydrochloride)
NAMENDA 20 mg daily,
ONGLYZA
7/31/09
5/24/13
Clinical
No dosage adjustment is
(Saxagliptin)
pharmacology
recommended based on gen-
pharmacokinetics between
approximately 25 % higher
(continued)
48
Date of
Date of
the cited
apparent clearance of
pharmacokinetic analysis.
POTIGA
6/10/11
9/6/13
Clinical
The impact of gender on the
(Ezogabine)
pharmacology
pharmacokinetics of
were approximately 20 %
approximately 30 % higher in
no gender difference in
weight-normalized clearance.
dosage of POTIGA is
recommended based on
gender.
SANCTURA
5/28/04
7/23/12
Clinical
Studies comparing the phar(Trospium
pharmacology
macokinetics in different
Chloride)
administered to 16 elderly
When 20 mg SANCTURA
(continued)
Date of
Date of
the cited
name)
approval
label
section
Labeling statement
26 % and 68 % higher,
SIMPONI
4/24/09
12/27/13
Clinical
Population PK analyses
(Golimumab)
pharmacology
suggested no PK differences
TEFLARO
10/29/10
12/16/13
Clinical
Following administration of a
(Ceftaroline
pharmacology
single 600 mg IV dose of
Fosamil for
recommended based on
gender.
TOVIAZ
10/31/08
8/1/12
Clinical
Following a single 8 mg oral
(Fesoterodine
pharmacology
dose of fesoterodine, the
Fumarate)
(continued)
50
Date of
Date of
the cited
5-hydroxymethyl tolterodine
67 years) were
nificantly influenced by
gender.
VICTOZA
1/25/10
6/13/13
Clinical
Based on the results of popu(Liraglutide)
pharmacology
lation pharmacokinetic ana-
on gender.
VFEND
5/24/02
4/7/14
Clinical
In a multiple oral dose study,
(Voriconazole)
pharmacology
the mean Cmax and AUC
voriconazole concentrations
(continued)
Date of
Date of
the cited
name)
approval
label
section
Labeling statement
VYVANSE
2/23/07
12/6/13
Clinical
Systemic exposure to dextro(Lisdexamfetamine
pharmacology
amphetamine is similar for
dimesylate)
to males.
one size fits all dose, leading to higher exposures in women due to their generally
lower body weight.
Sex differences have been reported for all four phases of drug disposition:
absorption, distribution, metabolism and excretion, (collectively abbreviated as
ADME) in humans and are discussed in more detail below. Other factors such as
anatomic, physiologic, biochemical and endocrine sex differences can also
influence drug disposition and response in humans (Mattison 2013) and are
further discussed below.
52
Some approved drug labelings have also reported PK sex differences from
population PK analysis with sparse PK sample data from Phase 2 and Phase 3
clinical trials (Table 2.1). The population PK model generated is used to explore
the effect of various covariates (factors) such as sex, age, ethnic group, and
smoking status on drug PK and can therefore be used to describe sex differences in
exposure (FDA Guidance for Industry 1999; Sun et al. 1999). Compared to
dedicated PK evaluation, the population PK approach encompasses some or all of
the following features (FDA Guidance for Industry 1999; Sun et al. 1999):
the collection of relevant PK information in patients who are representative of the
target population to be treated with the drug.
the identification and measurement of variability during drug development and
evaluation.
the explanation of variability by identifying factors of demographic, pathophysiological, environmental, or concomitant drug-related origin that may influence the
PK behavior of a drug.
the quantitative estimation of the magnitude of the unexplained variability in the
patient population.
Population PK analyses are now routinely performed during drug development
and the results for PK sex differences are included in several approved US drug
labelings including those for ofatumumab, gemifloxacin, perampanel, golimunab,
ceftaroline fosamil and liraglutide (Table 2.1).
53
Absorption
Sex differences in the gastrointestinal system have been demonstrated. For example,
gastric pH is higher in women than men and gastric and bowel transit times are usually
longer in women (Freire et al. 2011; Mojaverian et al. 1987). However, it is not clear
if the sex differences in gastric pH or gastric emptying have any clinical relevance. It
has been shown in one study that the rate of absorption of aspirin is higher in women
but there was no difference in the extent of absorption (Aarons et al. 1989). The
bioavailability of ethanol is greater in women compared to men partly due to
differences in volume of distribution (Vd) and gastric alcohol dehydro-genase activity
(Frezza et al. 1990) which may explain why there was no sex difference in alcohol
blood concentrations after intravenous administration (Baraona et al. 2001). There
may be differences in absorption depending on the drug route of administration (e.g.,
oral, inhalation, dermal, subcutaneous, rectal, vaginal, intra-muscular, intrathecal,
intraperitoneal) because factors that influence absorption are both drug- and routespecific, but may also be sex-specific. Most drugs are admin-istered through the oral
route following which absorption may be affected by sex differences in intestinal
metabolism cytochrome P-450 (CYP) enzymes and active transporter p-glycoprotein
(P-gp) (Gandhi et al. 2004; Waxman and Holloway 2009) (see below). Some studies
have shown that concentrations of inhaled aerosol drugs such as cyclosporine and
ribavirin are less in women compared to men but the clinical significance is unknown
(Rhatagi et al. 2000; Knight et al. 1988) and the bioavailability of intramuscular
cephradine is lower in women (Vukovich et al. 1975). Additionally, women have
greater minute ventilation and a lower tidal volume, both of which may have the
potential to affect drug absorption via the respiratory tract. Inactive ingredients may
affect the bioavailability of drug formu-lations and this could occur in a sex-specific
way, at least in some cases. For example, the excipient polyethylene glycol enhances
the bioavailability of ranitidine in men (up to 63 %), whereas it is decreased in women
(up to 24 %) (Ashiru et al. 2008).
Sex differences have been reported in bioavailability of medicines, which is then used
to establish bioequivalence (BE) of generic drugs. Analysis of sex differences in
intrasubject variability and PK from 26 BE studies showed that although there was no
sex difference in intrasubject variability, there was a _20 % difference in PK
parameters in one third of the data set (Chen et al. 2000). The PK sex differences
were primarily the result of greater exposure in women who were given the same dose
as men. When the parameters were corrected for weight, only 15 % showed
54
Distribution
Since body composition varies by sex, there are also sex differences in drug
distribution. Women have a higher percentage of body fat compared to men
(approximately 25 % vs. 16 % in men), although this difference decreases as age
increases (Vahl et al. 1998). Due to this larger amount of lipophilic tissue, women
have a greater Vd for lipophilic drugs such as diazepam, nitrazepam, chlordiazepoxide and cyclosporine (Soldin and Mattison 2009; Ochs et al. 1981;
Greenblatt et al. 1980; Greenblatt et al. 1985; Roberts et al. 1979; Kahan et al.
1986). Increased Vd may translate into prolonged elimination half-life, tissue
accumulation over time, and exposure-related adverse reactions. Conversely,
women have a smaller volume of distribution for hydrophilic drugs, such as
propanol (Ernstgard et al. 2003). Women are also reported to have a lower
plasma volume when compared to men, as well as a lower organ blood-flow rate
and lower concentrations of -1 acid glycoprotein (Piafsky and Borga 1977;
Verbeeck et al. 1984), a binding protein for neutral and basic drugs which may
impact the distribution process leading to different exposures. As opposed to
albumin, -1 acid glycoprotein has its expression controlled by circulating sex
hormones (Beierle et al. 1999). Hor-monal contraceptives and pregnancy both
further decrease plasma -1 acid glyco-protein. As a result, the unbound fraction
of various drugs that bind to -1 acid glycoprotein is significantly higher in
females than in males, as described for diazepam, chlordiazepoxide, and
imipramine (Ochs et al. 1981; Greenblatt et al. 1980; Roberts et al. 1979;
Kristensen 1983). However, no sex differences have been found in the unbound
fractions of verapamil and disopyramide or other highly bound drugs in patients
receiving oral contraceptives (Keefe et al. 1981; Kishino et al. 1995; Gleichmann
et al. 1973).
According to the free drug hypothesis, (which states that the pharmacological
activity is correlated with unbound drug concentrations in plasma) this should
translate into more drug being able to penetrate tissues, but the clinical impact of
protein binding of drugs has not been elucidated (Rolan 1994).
Metabolism
The liver plays an important role in the metabolism of many drugs. Hepatic drug
metabolism is mainly by two phases- Phase I, which includes oxidation, reduction,
CYP
Sex differences in
enzyme
activity
Examples of substrate drugs
CYP1A2
Women < men
product labeling)
CYP2D6
Women < men
Dextromethorphan, Metoprolol (Anderson 2005; Labbe
et al. 2000)
Women men
Debrisoquin (Bebia et al. 2004)
CYP3A
Women > men
Midazolam, Nifedipine, Triazolam (Greenblatt and von
CYP2C9
Women men
Fluvastatin (Schwartz 2003)
CYP2C19
Women men
Mephenytoin (Bebia et al. 2004)
The CYP superfamily has a diverse range of enzymes responsible for drug
metabolism, and various enzymes have sex-related differences in activity. Caffeine
is metabolized by CYP1A2. This isoenzyme also metabolizes drugs such as theophylline and clozapine. Studies have shown a higher activity of CYP1A2 in men
than in women (Anderson 2005). In one study, women had a 35 % higher concentration of clozapine compared with men after normalization for dose, age, and
body weight (Lane et al. 1999). The sex differences among major CYP enzymes
are summarized in Table 2.2.
CYP2D6 is the second most common enzyme involved in therapeutic drug
biotransformation (Franconi et al. 2007). It metabolizes several drugs including
antidepressants, antiarrhythmics, analgesics, and beta blockers. Although there
have been reports showing faster clearance of CYP2D6 substrates (such as dextromethorphan and metoprolol) in men than in women, there have been other reports
showing either no sex-based differences or higher CYP2D6 activity in women
(Labbe et al. 2000; Bebia et al. 2004).
CYP3A enzymes are the most common CYPs for metabolism, metabolizing greater
than 50 % of commonly prescribed drugs. Many drugs that are substrates for CYP3A
exhibit higher clearance in women leading to lower exposure (Franconi et al. 2007;
Mattison 2013; Greenblatt and von Moltke 2008; Chetty et al. 2012). For example,
Midazolam is a well-known substrate for CYP3A. A meta-analysis (Hu and Zhao
2010) on sex-dependent differences in midazolam disposition for both intravenous and
oral exposures showed that women had higher clearance rates than men, and the sex
differences were more pronounced for intravenous midazolam. There was no
difference in oral bioavailability between the sexes. The authors concluded that women
exhibited significantly greater hepatic CYP3A activity than men. Similarly, an earlier
study that analyzed 38 datasets for 14 CYP3A substrate drugs tested in healthy young
males and females showed a difference in the overall mean ratios of female to male
weight-normalized clearance of the drugs (parenteral drugs: 1.26 _ 0.07; oral drugs:
1.17 _ 0.07), i.e., women cleared the drugs faster than men and sex differences were
more pronounced for intravenous route (Greenblatt and von Moltke 2008). They also
looked at absolute bioavailability of the oral drugs and identified no difference in this
parameter
56
between males and females. The authors concluded that gender had a small and
statistically significant influence on CYP3A metabolism, although they felt that it
was probably not clinically important (Greenblatt and von Moltke 2008).
CYP2C9 and CYP2C19 do not appear to have significant sex differences in
activity (Schwartz 2003; Anderson 2005).
In addition to sex differences observed in Phase I metabolism, Phase II metabolism also has shown sex differences. However, these Phase II enzymes have not
been as extensively studied as the CYP enzymes. Phase II enzymes such as
glucoronyltransferases and methyltransferases are generally faster in men
(Franconi et al. 2007). However, there have been data that suggest that there are
sex differences in the glucorondination of some drugs and not others (Franconi et
al. 2007). Another consideration is that many drugs go through multiple metabolic pathways, which can contribute to widely varying sex differences. Because
women take more prescription medicines (see Chap. 14) and more OTC/herbal
products (see Chap. 13) than men (Franconi et al. 2007) women have a greater
possibility of exposure differences simply due to a higher frequency of possible
drug interactions (Gurwitz 2005).
Excretion
The kidney is the major organ of drug excretion of both parent drug compounds
and drug metabolites. There are known sex differences in all three renal processes
for renal clearance glomerular filtration, tubular secretion, and tubular
reabsorption (Fig. 2.1). Renal clearance is generally higher in men than in women
(Gaudry et al. 1993; Berg 2006). This is accounted for by body weight
differences, since glomerular filtration is directly proportional to lean body weight.
Men have signifi-cantly higher creatinine clearance compared to women, but this
difference dimi-nishes once results are adjusted for weight. There are sex-specific
algorithms available for routine estimation of glomerular filtration or creatinine
clearance to guide dosing of renally cleared medications to reduce adverse effects
due to exposure differences in men and women (Cockcroft and Gault 1976;
Manjunath et al. 2001). There is also some evidence that drugs that are actively
secreted or reabsorbed by the kidney may also show sex difference in rates of
excretion (due to possible sex-based differences in transporter activities). For
example, one study in humans has shown that renal clearance of amantadine, an
organic cation transported by organic cation transporters in the kidney, is increased
in men compared to women (Gaudry et al. 1993).
Transporters
Transporters are membrane-bound proteins that translocate endogenous com-pounds or
drugs across the membrane (Giacomini and Sugiyama 2006; Giacomini and Huang
2013). They are expressed in all tissues including intestine, liver, kidney
57
and brain. They work in concert with metabolizing enzymes in the absorption,
distribution, metabolism and excretion of drugs, thus affecting exposure to the
medicine. Similar to enzymes, sex discrepancies in transporter expression probably
contribute to disparities in drug disposition and toxicity between men and women. Sex
differences in the expression of transporters in rodents have been reported. For
example, a number of liver transporters demonstrate female predominant (Oatp1a4,
_1a6, _2b1, Ntcp, Mrp4, Mate1) or male-predominant (Oatp1a1, Bcrp, Abca1) mRNA
expression patterns in mice (Klaassen and Aleksunes 2010). However, data regarding
sex differences in human transporters are quite limited.
P-gp encoded by MDR1 gene is an efflux transporter that expresses in multiple tissues
including intestine, liver, and kidneys. Sex differences in the expression of P-gp in the
gut have been studied showing a lower level in female enterocytes or no difference
among sex (Gandhi et al. 2004; Waxman and Holloway 2009; Potter et al. 2004;
Paine et al. 2005), and a higher expression of P-gp has been reported in male liver
biopsy samples (Schuetz et al. 1995). In addition, in the literature there are reports that
expression of another efflux transporter, Breast Cancer Resistant Protein (BCRP), is
+
higher in male liver than in female liver (Merino et al. 2005). More Na -dependent
58
quantification methodology showed that sex was not associated with transporter
protein expression of OATP1B1, OATP1B3, OATP2B1, and P-gp in frozen human
livers (Prasad et al. 2014). There is a need for characterization of sex differences in
human transporter proteins to more clearly understand any possible clinical effects.
Hormonal Differences
The assessment of sex-related differences is important as women experience a
changing internal hormonal environment during the menstrual cycle (follicular,
ovulatory, and luteal phases), during pregnancy, as well as during and following
menopause. Furthermore, hormonal contraceptives can lead to increased or
decreased drug clearance, most likely due to induction and/or inhibition of CYP
isoforms in the liver and gut.
There are numerous examples supporting the contention that female sex hormones impact drug-metabolizing pathways (Schwartz 2003; Gandhi et al. 2004;
Kashuba and Nafziger 1998; Bigos et al. 2009). Increased levels of estrogen and
progesterone alter hepatic enzyme activity, which can increase accumulation or
decrease elimination of some drugs. Estrogen is a substrate for CYP3A4 and
CYP1A2 and it has been shown that antidepressant metabolism may be significantly impacted during the late luteal phase of the menstrual cycle or with
estrogen replacement therapy (Bigos et al. 2009). Physiological changes during
pregnancy in the cardiovascular, respiratory, renal, gastrointestinal, endocrine and
hematologic/ coagulation systems may also induce profound alterations to the PK
of many drugs and thus the response to these drugs (Costantine 2014; Mattison et
al. 1991). Additionally, changes in Vd and elimination rates may modify the PK
of drugs in pregnant women during gestation. The clinical relevance of these
changes is less certain (Loebstein et al. 1997).
Although sex hormones are thought to play a dominant role in modulating sexbased differences in PK, studies examining this theory have yielded conflicting
results. For example, midazolam clearance (reflecting CYP3A4 metabolic
activity) failed to show fluctuations during the menstrual cycle (Kharasch et al.
1999) and studies of eletriptan (another CYP3A substrate) demonstrated no sexrelated or menstrual cycle-related differences (Shah et al. 2001).
59
Considerations
A few examples where sex-based PK differences resulted in modified pharmacological response and/or subsequent different recommendations are highlighted here.
60
Ondansetron
Ondansetron, approved for the prevention of nausea and vomiting resulting from
chemotherapy or in the postoperative setting, has been shown to display a significant PK sex difference (Jann et al. 1998). The FDA-approved labeling for
ondansetron states that women have 1.52 times the peak drug plasma concentrations and a lower oral clearance, but no sex-based dosage adjustment is
Olanzapine
Olanzapine is an atypical antipsychotic approved for the treatment of schizophrenia
and bipolar disorder for which the label recommends a lower dose for patients in
whom higher exposures are anticipated. For schizophrenia, the starting dose is 5 10
mg daily with a target dose of 10 mg/day within several days (Zyprexa US FDA
product labeling). However, given that some treatment related adverse events are dose
and exposure dependent, a lower dose is recommended in specific populations who
may have higher plasma concentrations. For instance, olanzapine clearance is lower in
women. Clearance is also lower in the elderly (_65 years), causing higher plasma
concentrations. Olanzapine is extensively metabolized and CYP1A2 has been
identified as one of the enzymatic pathways of metabolism. As noted earlier, CYP1A2
shows a lower activity in women, possibly leading to a lower clearance of olanzapine
in women. CYP1A2 can be induced by cigarette smoking and as a result, olanzapine
clearance is about 40 % higher in smokers than in nonsmokers.
Although each of these factors may not independently justify dosing adjustment, the
combined effects of age, smoking, and a patients sex could lead to substantial PK
differences and increase the likelihood of adverse effects from higher expo-sures. The
plasma concentrations in elderly nonsmoking females, for example, may be higher
than those in young smoking males. The labeling for olanzapine recom-mends a lower
starting dose of 5 mg daily for patients who exhibit a combination of factors (e.g.,
nonsmoking female patients _65 years of age), as higher plasma concentrations are
Male (%)
Female (%)
Male (%)
Female (%)
Adverse event
(N 1,218)
(N 512)
(N 914)
(N 336)
Edema
5.6
14.6
1.4
5.1
Flushing
1.5
4.5
0.3
0.9
Palpitations
1.4
3.3
0.9
0.9
Somnolence
1.3
1.6
0.8
0.3
61
Amlodipine
Amlodipine is a long-acting calcium channel blocker indicated for the treatment of
hypertension and coronary artery disease. The recommended adult starting dose is
5 mg once daily with a maximum dose of 10 mg once daily, however, a lower
starting dose of 2.5 mg once daily is recommended for small, fragile, or elderly
patients or patients with hepatic impairment. The labeling contains information on
the adverse effects of the higher dose in women, which is most likely related to
higher blood levels. For several adverse experiences that appear to be drug- and
dose-related, there was a greater incidence in women than in men associated with
Zolpidem
Zolpidem, a sedativehypnotic medicine used in adults for the treatment of insom-nia,
displays PK sex differences. The rate (measured by the peak plasma concen-tration or
Cmax) and extent (measured by the area under the plasma concentration-time curve or
AUC) of absorption of zolpidem following oral absorption were both approximately
45 % higher in women compared to men for immediate-release zolpidem and
approximately 50 % and 75 % higher, respectively, for controlled-release zolpidem
Ambien US FDA product labeling with a lower dose of 5 mg for the elderly (who had
higher blood levels of the drug the next morning)
62
and for patients with hepatic impairment who metabolized the drug more slowly
(Farkas et al. 2013).
zolpidem levels after use of extended-release zolpidem products (Ambien controlledreleased products at 12.5 mg), which is expected given that approximately 33 % of
women and 25 % of men had zolpidem blood concentrations exceeding 50 ng/mL 8 h
post-dosing. In studies of zolpidem extended-release 6.25 mg, at 8 h after dosing,
about 15 % of adult women and 5 % of adult men had a zolpidem level of _50 ng/mL,
whereas for both elderly men and women, about 10 % had such a zolpidem level
(Ambien CR). These findings are consistent with the sex differences observed with
various formulations of zolpidem. In January 2013, the FDA lowered the
recommended dose for zolpidem, in particular for women ( FDA drug safety
communication: FDA approves. . .; FDA drug safety communication: risk of. . .) and
included these recommendations in the labeling for all the zolpidem formulations
Although the labeling of zolpidem products also suggests that the lower doses
should be considered for men, the stronger recommendation for reduced dosage in
women underscores the clear sex-associated differences in zolpidem PK observed
in studies. A study of patients in the Taiwan National Health Insurance reimbursement database has shown that even the use of zolpidem for one day prior might be
associated with an increased risk of motor vehicle accidents (Yang et al. 2011).
These sex-specific labeling recommendations reflect an evidence-based approach
to risk management and dose individualization. These examples suggest that both
the exposure differences as well as the corresponding response changes are
considered when dosing adjustments are recommended in labeling.
63
Are there differences in PK between men and women other than those resulting
from body weight differences?
What are the effects of oral contraceptives and hormonal replacement therapy on
metabolism of drugs? What drugs affect the efficacy of oral contraceptives? (see
Chap. 5 for more detail)
In general, are there more adverse event reports resulting from exposure differences in women as compared with men? Is this due to a higher percentage of use,
higher reporting, or increased sensitivity of certain adverse events in women? The
issues around whether women experience more adverse drug reactions than men is
complex, but the evidence (discussed more in Chap. 14 on primary care
prescribing) suggests they do have higher rates which are not just due to higher
rates of use and reporting.
When should drugs be labeled differently for women and men based on PK sex
differences?
Sex is one of many factors that can affect a drugs PK. Tools need to be developed
that can evaluate the effect of multiple intrinsic and extrinsic factors on PK of an
individual patient. A computational tool such as physiologically-based PK (PBPK)
modeling can integrate multiple factors in the system model to simulate the effect
from multiple intrinsic (including sex) and extrinsic (including concom-itant
medications) factors on the PK of a drug. Recently, PBPK models have been used
in drug development to assist in clinical trial design and answer what if
questions (Rowland et al. 2011; Huang and Rowland 2012). Such models can be
used to predict and understand why sex differences observed for certain drugs but
not others by considering multiple factors.
Conclusions
Women and men differ in numerous physical parameters. Among others, women
have a lower total body weight, a higher proportion of body fat, a lower body
surface area, a lower muscle mass, smaller organ size, lower glomerular filtration
rate, and lower gastric acid excretion factors that may influence drug disposition.
Physiological differences, such as hormonal fluctuations during the menstrual
cycle, may also influence drug PK. Menstrual cycle variations do occur in renal,
cardiovascular, and hematological systems, with the potential to impact protein
binding and volume of distribution. Similarly, hormonal changes during menopause, pregnancy, and hormonal contraceptive therapy are likely to have the same
effects. Finally, there are molecular factors that account for sex differences in PK
(e.g., difference in drug-metabolizing enzymes and transporters). These physical,
physiological, and molecular factors may influence the processes that determine
drug disposition (i.e., ADME) (Nicolas et al. 2009).
Understanding the mechanisms of sex differences in drug therapy is critical for optimal
dosing in both sexes. Evaluation of sex differences in PK of drugs will further enhance
understanding of sex-based differences in the safety and efficacy of
64
drugs and minimize therapeutic adverse events. PK differences are the most
common sex differences and early detection of these differences during drug
development can lead to clinical trial design that will use sex-based dosing and
better individualization of therapy. Because men and women may differ in specific
drug PK it is essential to understand those sex differences in drug disposition and
response, as in turn they may affect drug safety and effectiveness.
In conclusion, several mechanisms relevant to drug absorption and disposition have
been shown to exert sex-specific activity differences, and for some drugs these have
the potential to result in clinically relevant differences in pharmacological response.
Thus, the importance of the evaluation of sex-specific PK during drug development is
to optimize therapy for both men and women which is highlighted by the regulatory
requirements and guidance recommendations.
References
Aarons L, Hopkins K, Rowland M et al (1989) Route of administration and sex differences in the
pharmacokinetics of aspirin, administered as its lysine salt. Pharm Res 6:660666
65
66
67
Keefe D, Yee Y, Kates R (1981) Verapamil protein binding in patients and normal subjects. Clin
Pharmacol Ther 29:2126
Kharasch ED, Mautz D, Senn T et al (1999) Menstrual cycle variability in midazolam pharmacokinetics. J Clin Pharmacol 39(3):275280
Kim JS, Nafziger AN (2000) Is it sex or is it gender? Clin Pharmacol Ther 68(1):13
Kishino S, Nomura A, Di Z et al (1995) Alpha-1acid glycoprotein concentration and the protein
binding of diopyramide in healthy subjects. J Clin Pharmacol 35:510514
Klaassen CD, Aleksunes LM (2010) Xenobiotic, bile acid, and cholesterol transporters: function
and regulation. Pharmacol Rev 62(1):196
Knight V, Yu C, Gilbert B et al (1988) Estimating the dosage of ribavirin aerosol according to age
and other variables. J Infect Dis 158:443447
Kristensen CB (1983) Imipramine serum protein binding in healthy subjects. Clin Pharmacol
Ther 34(5):689694
Labbe L, Sirois C, Pilote S et al (2000) Effect of gender, sex hormones, time variables and
physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker
substrates. Pharmacogenetics 10(5):425438
Lane HY, Chang YC, Chang WH et al (1999) Effects of gender and age on plasma levels of
clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry 60(1):3640
Loebstein R, Lalkin A, Koren G (1997) Pharmacokinetic changes during pregnancy and their
clinical relevance. Clin Pharmacokinet 33(5):328343
Manjunath G, Sarnak M, Levy A (2001) Prediction equations to estimate glomerular filtration
rate: an update. Curr Opin Nephrol Hypertens 10:785792
Mattison DR (2013) Pharmacokinetics in real life: sex and gender differences. J Popul Ther Clin
Pharmacol 20(3):e340e349
Mattison DR, Blann E, Malek A (1991) Physiological alterations during pregnancy: impact on
toxicokinetics. Fundam Appl Toxicol 16(2):215218
Meibohm B, Beierle I, Derendorf H (2002) How important are gender differences in pharmacokinetics? Clin Pharmacokinet 41(5):329342
Merino G, van Herwaarden AE, Wagenaar E et al (2005) Sex-dependent expression and activity
of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver.
Mol Pharmacol 67(5):17651771
Mojaverian P, Rocci ML Jr, Corner DP et al (1987) Effect of food on the absorption of entericcoated aspirin: correlation with gastric residence time. Clin Pharmacol Ther 41:1117
Nicolas JM, Espie P, Molimard M (2009) Gender and interindividual variability in pharmacokinetics. Drug Metab Rev 41(3):408421. doi: 10.1080/10837450902891485
68
Rademaker M (2001) Do women have more adverse drug reactions? Am J Clin Dermatol 2(6):
349369351
Rhatagi S, Calic F, Harding N et al (2000) Pharmacokinetics, pharmacodynamics, and safety of
inhaled cyclosporin A (AD1628) after single and repeated administration healthy male and
female subjects and asthmatics patients. J Clin Pharmacol 40:12111226
Roberts RK, Desmond PV, Wilkinson GR et al (1979) Disposition of chlordiazepoxide: sex
differences and effects of oral contraceptives. Clin Pharmacol Ther 25:826831
Rolan PE (1994) Plasma protein binding displacement interactions why are they still regarded
as clinically important? Br J Clin Pharmacol 37(2):125128
Rowland M, Peck C, Tucker G (2011) Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 51:4573. doi: 10.1146/annurevpharmtox-010510-100540
Schuetz EG, Furuya KN, Schuetz JD (1995) Interindividual variation in expression of pglycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther
275(2): 10111018
Schwartz JB (2003) The influence of sex on pharmacokinetics. Clin Pharmacokinet 42(2):107
121 Schwartz JB (2007) The current state of the knowledge on age, sex and their interactions on
clinical pharmacology. Clin Pharmacol Ther 82(1):8789
Shah AK, Laboy-Goral L, Scott N et al (2001) Pharmacokinetics and safety of oral eletriptan
during different phases of the menstrual cycle in healthy volunteers. J Clin Pharmacol 41(12):
13391344
Soldin OP, Mattison DR (2009) Sex differences in pharmacokinetics and pharmacodynamics.
Clin Pharmacokinet 48(3):114157
Sun H, Fadiran EO, Jones CD et al (1999) Population pharmacokinetics: a regulatory
perspective. Clin Pharmacokinet 37(1):4158
Tran C, Knowleges SR, Liu BA et al (1988) Gender differences in adverse drug reactions. J Clin
Pharmacol 38:10031009
Vahl N, Moller N, Lauritzen T et al (1998) Metabolic effects and pharmacokinetics of a growth
hormone pulse in healthy adults: relation to age, sex, and body composition. J Clin Endocrinol
Metab 82:36123618
Verbeeck R, Cardinal JA, Wallace S (1984) Effect of age and sex on the plasma binding of acidic
and basic drugs. Eur J Clin Pharmacol 27:9197
Vukovich RA, Brannick LJ, Sugerman AA et al (1975) Sex differences in the intramuscular
absorption and bioavailability of cephradine. Clin Pharmacol Ther 18(2):215220
Waxman DJ, Holloway MG (2009) Sex differences in the expression of hepatic drug
metabolizing enzymes. Mol Pharmacol 76:215228
Yang Y, Lai J, Lee C et al (2011) Increased risk of hospitalization related to motor vehicle
accidents among people taking zolpidem: a casecrossover study. J Epidemiol 21(1):3743. doi:
10.2188/jea.JE20090195
http://www.springer.com/978-3-319-12405-6